Kinetics of humoral response in children with acute lymphoblastic leukemia immunized with influenza vaccine in 1993 in poland

Brydak, Lidia B.; Rokicka-Milewska, R; Jackowska, Teresa; Rudnicka, H; Regnery, Helen L.; Cox, Nancy J.

doi:10.3109/10428199709109171

Cited by 32 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In spite of this fact, the humoral immune response to influenza vaccine observed in these patients did not weaken, as many authors suggest [26–29]. This is clearly seen when the results of this study are compared with data obtained in our previous investigation on seroconversion in once‐immunized hemophiliac children [30]. In the case of children vaccinated in 1993–94 and then in 1996–97, the proportion of subjects protected 6 months after influenza vaccination ranged from 76.3% to 97.4%, while in hemophiliac patients immunized only in 1993–94 it was almost the same, i.e.…”

Section: Discussionsupporting

confidence: 63%

Efficacy of subunit trivalent influenza vaccine in previously vaccinated children suffering from hemophilia

Brydak

Rokicka-Milewska

Machała

et al. 1998

Clinical Microbiology and Infection

Self Cite

View full text Add to dashboard Cite

OBJECTIVE: To assess humoral immune response to subunit trivalent influenza vaccine in children suffering from hemophilia who had been immunized for the first time in 1993-94 and then in 1996-97. METHODS: In autumn 1996-97, 38 previously vaccinated hemophiliac patients were subcutaneously immunized with a single 0.5-mL dose of subunit influenza vaccine containing the following three virus strains: A/Singapore/6/86 (H1N1), A/Wuhan/359/95 (H3N2) and B/Beijing/184/93 (HB). Antibody response to influenza vaccine was measured before vaccination, 3 weeks after vaccination and 6 months after vaccination, by use of hemagglutinin- and neuraminidase-inhibition tests. To present the level of seroconversion, geometric mean titers of anti-influenza antibodies, mean fold increase, protection rate and conversion rate were determined. All results were compared with the control group of 23 healthy persons who had never been vaccinated against influenza and for whom the same serologic tests were carried out as for the vaccinated group. RESULTS: Three weeks after immunization, antihemagglutinin antibody levels were 3.9-10.9 times higher than before vaccination, but the highest mean fold increase values were recorded 6 months after vaccination, ranging from 8.4 to 28.6. In the case of neuraminidase, mean fold increases of antibodies reached values of 3.6-12.3 three weeks after vaccination and 7.1-29.1 six months after vaccination. The highest proportion of subjects protected was observed 6 months after immunization and ranged from 76.3% to 97.4%, compared to 52.6-60.5% 3 weeks after vaccination. Similar values were obtained for conversion rate: 71.1-86.8% 6 months after vaccination, in comparison with 39.5-42.1% 3 weeks after immunization. CONCLUSIONS: All data obtained in the present study indicate a significant immune response to subunit trivalent influenza vaccine in patients suffering from hemophilia; this is additionally confirmed by the fact that none of the vaccinated children were infected with the influenza virus and no serious adverse reactions were observed after administration of the vaccine.

show abstract

Section: Discussionsupporting

confidence: 63%

Efficacy of subunit trivalent influenza vaccine in previously vaccinated children suffering from hemophilia

Brydak

Rokicka-Milewska

Machała

et al. 1998

Clinical Microbiology and Infection

Self Cite

View full text Add to dashboard Cite

show abstract

“…If the latter explanation is correct, it may be that annual immunisation prior to the influenza season in children with cancer is of greater benefit than suggested by the change in the proportions of patients with protective antibody titres following immunisation, because it may reduce loss of protective immunity in some patients as well as facilitating new protective immunity in others. In one study of leukaemic children on and off treatment, antibody levels returned to baseline by 12 months following vaccination,17 but in other children, mainly off treatment, levels were maintained at least until six months following vaccination,21 22 suggesting that protection would be maintained during the highest risk time for influenza even if it is subsequently lost. Taken with previous data, our study suggests that the risk of influenza infection in children with cancer may be reduced substantially by immunisation.…”

Section: Discussionmentioning

confidence: 99%

Response to influenza immunisation during treatment for cancer

et al. 2001

View full text Add to dashboard Cite

Aims-To assess the annual risk of influenza infection in children with cancer and the immunogenicity of a trivalent split virus influenza vaccine in these children. Methods-Eighty four children with cancer were tested for susceptibility to the circulating strains of influenza virus in autumn 1995 and 1996. Non-immunised children were reassessed the following spring for serological evidence of natural infection. Forty two patients received two doses of influenza vaccine. These children were receiving continuing chemotherapy for acute lymphoblastic leukaemia or were within six months of completing chemotherapy. Results-Among the 84 children tested for influenza virus susceptibility only 8% of patients were fully protected (antibody titres > 40) against all three of the prevalent influenza virus strains; 33% were susceptible to all three viruses. Evidence of acquired natural infection was seen in 30% of unimmunised patients. Among immunised susceptible patients, 66% made some protective response to the vaccine and 55% showed protective antibody titres to all three viral strains following vaccination. Older age was associated with increased response to the H1N1 and H3N2 vaccine components, but total white cell count or neutrophil count at immunisation, type of cancer, or length of time on treatment for acute lymphoblastic leukaemia did not aVect response. Conclusions-Most children with cancer studied were at risk of influenza infection. A significant response to immunisation was seen, supporting annual influenza vaccination for children being treated for cancer. (Arch Dis Child 2001;84:496-500)

show abstract

“…The literature, however, suggests that many of these individuals will have an inadequate response or be unable to develop a protective antibody titer to a variety of vaccines being administered. 28 Serologic conversion rates of 19%-93% have been reported in adults with various malignancies, but patients with Hodgkin's disease and non-Hodgkin's lymphoma have demonstrated poor responses to multi-antigen vaccines as well as single antigen vaccines, including influenza vaccines, as compared to patients with solid tumors or non-hematologic malignancies. [29][30][31][32][33] Prior exposure to influenza virus and previous influenza vaccinations have also been shown to suppress the production of antibodies and therefore influence the response to new influenza vaccines.…”

Section: Discussionmentioning

confidence: 99%